Cerevel Therapeutics Company
Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson’s disease and substance use disorder.
Headquarters:
Boston, Massachusetts, United States
Funding Status:
IPO
Founded Date:
2018-10-01
Last Funding Type:
Post-IPO Equity
Investors Number:
19
Last Funding Date:
2021
Employee Number:
101-250
Total Funding:
1145000000
Industry:
Neurotech